

W/D

1646  
Box Sep.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

JENSEN et al.

Group Art Unit: 1646

Serial No.: 09/060,294

Examiner: D. Romeo

Filed: April 15, 1998

For: MODIFIED TNF- $\alpha$  MOLECULES, DNA ENCODING SUCH AND VACCINES COMPRISING SUCH  
MODIFIED TNF- $\alpha$  AND DNA



TRANSMITTAL

Assistant Commissioner of Patents  
Washington, D.C. 20231



RECEIVED

JUL 26 1999

Sir:

TECH CENTER 1600/2900

Transmitted herewith are an Amendment, Sequence Listing and MS-DOS Compatible Sequence Listing in the above-captioned patent application.

The fee has been calculated as shown below:

	Claims Remaining After Amendment	Highest Number Previously Paid For	Present Extra	Small Entity Rate Addit. Fee	(or)	Other Than A Small Entity Rate Addit. Fee
Total	39	-	39 =	0	x 09 = \$	x 18 = \$
Indep.	05	-	05 =	0	x 39 = \$	x 78 = \$
___ First Presentation of Multiple Dependent Claims				+130 = \$		+ 260 = \$
Total Additional Fee				\$		\$

XXXX If a Petition for Extension of Time is necessary and the Petition and/or the check is not enclosed, this will act as the Petition and applicant herewith petitions the Commissioner to extend the time for response and charge any fees necessary under 37 CFR 1.17 (a)(1)-(5) to Deposit Account No. 06-1358. The Commissioner is also authorized to charge payment of any other additional fees associated with this communication or credit any overpayment to Deposit Account No. 06-1358. A duplicate copy of this sheet is attached.

Respectfully submitted,

JACOBSON, PRICE, HOLMAN & STERN, PLLC

By: \_\_\_\_\_

D. Douglas Price  
Registration No. 24,514

400 Seventh Street, N.W.  
Washington, D.C. 20004-2201  
Atty. Docket No.: 162/P60953US1  
Telephone: (202)638-6666  
Date: July 23, 1999  
DDP/PLC:dlb  
S:\LANDESK\HOME\SHARED\VP60953.TRS

PATENT  
ATTY. DOCKET NO.: 162/P60953US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

JENSEN et al.

Serial No.: 09/060,294

Filed: April 15, 1998



Group Art Unit: 1646

Examiner: D. Romeo

For: MODIFIED TNF- $\alpha$  MOLECULES, DNA ENCODING SUCH AND VACCINES  
COMPRISING SUCH MODIFIED TNF- $\alpha$  AND DNA

#7B w/ Disk  
08  
05  
99

A M E N D M E N T

Assistant Commissioner  
of Patents  
Washington, D.C. 20231

July 23, 1999

Sir:

Applicants respond to the Office Action (Paper No. 6) mailed  
June 23, 1999, as follows:

In order to comply with the Sequence Rules, namely, 37 CFR  
§ 1-821 - § 1.825, Applicant submits the following:

- (1) Substitute paper copy of Sequence Listing; and
- (2) Computer Readable Form (CRF) of Sequence Listing.

The content of the computer readable form and the paper copy  
are the same and, where applicable, include no new matter, as  
required by 37 CFR § 1.821(e) - (g) or § 1.825(b) or (d).

Serial No.: 09/060,294  
Atty. Docket No.: 162/P60953US1

Compliance with the Sequence Rules has been met. Notice thereof is awaited.

Respectfully submitted,

JACOBSON, PRICE, HOLMAN & STERN, PLLC



---


D. Douglas Price  
Registration No. 24,514

400 Seventh Street, N.W.  
Washington, D.C. 20004  
Telephone: (202) 638-6666  
Atty. Docket No.: 162/P60953US1  
Date: July 23, 1999  
DDP/PLC:dlb

S:\LANDESK\HOME\SHARED\P60953US1.CRF

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial ~~or substitute~~ computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**